Drugs facing NCE-1 in 2028
1. Alyftrek patent expiration
ALYFTREK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8754224 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(1 year, 7 months from now) | |
| US11639347 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(1 year, 11 months from now) | |
| US10239867 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(1 year, 11 months from now) | |
| US8623905 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(1 year, 11 months from now) | |
| US7645789 | VERTEX PHARMS INC | Indole derivatives as CFTR modulators |
May, 2027
(1 year, 11 months from now) | |
| US7495103 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(2 years from now) | |
| US7776905 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2027
(2 years from now) | |
| US10047053 | VERTEX PHARMS INC | Deuterated CFTR potentiators |
May, 2032
(7 years from now) | |
| US9181192 | VERTEX PHARMS INC | Deuterated CFTR potentiators |
May, 2032
(7 years from now) | |
| US8865902 | VERTEX PHARMS INC | Deuterated CFTR potentiators |
May, 2032
(7 years from now) | |
| US9512079 | VERTEX PHARMS INC | Deuterated CFTR potentiators |
May, 2032
(7 years from now) | |
| US11066417 | VERTEX PHARMS INC | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
Feb, 2039
(13 years from now) | |
| US11873300 | VERTEX PHARMS INC | Crystalline forms of CFTR modulators |
Aug, 2040
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629162 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2025
(a month from now) | |
| US8354427 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jul, 2026
(1 year, 2 months from now) | |
| US8410274 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(1 year, 7 months from now) | |
| US9931334 | VERTEX PHARMS INC | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(1 year, 7 months from now) | |
| US9670163 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(1 year, 7 months from now) | |
| US9974781 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(1 year, 11 months from now) | |
| US10022352 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Apr, 2027
(1 year, 11 months from now) | |
| US8598181 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(1 year, 11 months from now) | |
| US8324242 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Aug, 2027
(2 years from now) | |
| US8415387 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Nov, 2027
(2 years from now) | |
| US10646481 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(4 years from now) | |
| US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(4 years from now) | |
| US10081621 | VERTEX PHARMS INC | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
Mar, 2031
(5 years from now) | |
| US11578062 | VERTEX PHARMS INC | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
Mar, 2031
(5 years from now) | |
| US10058546 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof |
Jul, 2033
(8 years from now) | |
| US9012496 | VERTEX PHARMS INC | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
Jul, 2033
(8 years from now) | |
| US11951212 | VERTEX PHARMS INC | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
Apr, 2035
(9 years from now) | |
| US10206877 | VERTEX PHARMS INC | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
Apr, 2035
(9 years from now) | |
| US11866450 | VERTEX PHARMS INC | Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
Feb, 2039
(13 years from now) | |
| US12186306 | VERTEX PHARMS INC | Methods of treatment for cystic fibrosis |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2029 |
Drugs and Companies using DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM ingredient
NCE-1 date: 20 December, 2028
Market Authorisation Date: 20 December, 2024
Treatment: Treatment of a moderate to mild clinical phenotype of cf in patients aged 6 years and older who have at least one f508del mutation or another responsive mutation in the cftr gene with a pharmaceutical...
Dosage: TABLET
More Information on Dosage
ALYFTREK family patents
2. Attruby patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9642838 | BRIDGEBIO PHARMA | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
May, 2031
(6 years from now) | |
| US10513497 | BRIDGEBIO PHARMA | Process for preparing AG-10, its intermediates, and salts thereof |
Feb, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10398681 | BRIDGEBIO PHARMA | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
May, 2031
(6 years from now) | |
| US9913826 | BRIDGEBIO PHARMA | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
May, 2031
(6 years from now) | |
| US9169214 | BRIDGEBIO PHARMA | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
May, 2031
(6 years from now) | |
| US10842777 | BRIDGEBIO PHARMA | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
May, 2031
(6 years from now) | |
| US8877795 | BRIDGEBIO PHARMA | Identification of stabilizers of multimeric proteins |
May, 2031
(6 years from now) | |
| US11919865 | BRIDGEBIO PHARMA | Processes for preparing AG-10, its intermediates, and salts thereof |
Feb, 2038
(12 years from now) | |
| US11058668 | BRIDGEBIO PHARMA | Methods of treating TTR amyloidosis using AG10 |
Mar, 2039
(13 years from now) | |
| US12070449 | BRIDGEBIO PHARMA | Methods of treating TTR amyloidosis using AG10 |
Mar, 2039
(13 years from now) | |
| US11260047 | BRIDGEBIO PHARMA | Formulations of AG10 |
Aug, 2039
(14 years from now) | |
| US12005043 | BRIDGEBIO PHARMA | Formulations of AG10 |
Aug, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 22, 2029 |
| Orphan Drug Exclusivity(ODE-506) | Nov 22, 2031 |
Drugs and Companies using ACORAMIDIS HYDROCHLORIDE ingredient
NCE-1 date: 22 November, 2028
Market Authorisation Date: 22 November, 2024
Treatment: Treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (attr-cm)
Dosage: TABLET
More Information on Dosage
ATTRUBY family patents
3. Cobenfy patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10369144 | BRISTOL-MYERS | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(5 years from now) | |
| US10369143 | BRISTOL-MYERS | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(5 years from now) | |
| US10238643 | BRISTOL-MYERS | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(5 years from now) | |
| US10265311 | BRISTOL-MYERS | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(5 years from now) | |
| US10695339 | BRISTOL-MYERS | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
Jul, 2030
(5 years from now) | |
| US11452692 | BRISTOL-MYERS | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
Sep, 2039
(14 years from now) | |
| US10933020 | BRISTOL-MYERS | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
Sep, 2039
(14 years from now) | |
| US11471413 | BRISTOL-MYERS | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
Sep, 2039
(14 years from now) | |
| US10925832 | BRISTOL-MYERS | Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation |
Sep, 2039
(14 years from now) | |
| US11890378 | BRISTOL-MYERS | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
Sep, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 26, 2029 |
Drugs and Companies using TROSPIUM CHLORIDE; XANOMELINE TARTRATE ingredient
NCE-1 date: 26 September, 2028
Market Authorisation Date: 26 September, 2024
Treatment: Treatment of schizophrenia in adults
Dosage: CAPSULE
More Information on Dosage
COBENFY family patents
4. Crenessity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12128033 | NEUROCRINE | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine |
Jun, 2041
(16 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11730739 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| US10905690 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| US11311544 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 13, 2029 |
| Orphan Drug Exclusivity(ODE-503) | Dec 13, 2031 |
Drugs and Companies using CRINECERFONT ingredient
NCE-1 date: 13 December, 2028
Market Authorisation Date: 13 December, 2024
Treatment: Adjunctive treatment of classic congenital adrenal hyperplasia (cah)
Dosage: CAPSULE; SOLUTION
More Information on Dosage
CRENESSITY family patents
5. Duvyzat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7329689 | ITALFARMACO SPA | Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester |
Jan, 2026
(8 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9867799 | ITALFARMACO SPA | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
Feb, 2032
(6 years from now) | |
| US9421184 | ITALFARMACO SPA | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
Feb, 2032
(6 years from now) | |
| US10688047 | ITALFARMACO SPA | Physically and chemically stable oral suspensions of givinostat |
Oct, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2029 |
| Orphan Drug Exclusivity(ODE-473) | Mar 21, 2031 |
Drugs and Companies using GIVINOSTAT HYDROCHLORIDE ingredient
NCE-1 date: 21 March, 2028
Market Authorisation Date: 21 March, 2024
Treatment: A method for the treatment of duchenne muscular dystrophy (dmd) using givinostat
Dosage: SUSPENSION
More Information on Dosage
DUVYZAT family patents
6. Ensacove patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8551995 | XCOVERY | Kinase inhibitor compounds |
Feb, 2029
(3 years from now) | |
| US9296724 | XCOVERY | Substituted pyridazinecarboxamides as kinase inhibitors |
Jun, 2029
(4 years from now) | |
| US9126947 | XCOVERY | Substituted pyridazine carboxamide compounds |
Nov, 2031
(6 years from now) | |
| US10899744 | XCOVERY | Crystalline form of compound suppressing protein kinase activity, and application thereof |
Jun, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2029 |
Drugs and Companies using ENSARTINIB HYDROCHLORIDE ingredient
NCE-1 date: 18 December, 2028
Market Authorisation Date: 18 December, 2024
Treatment: Treatment of adult patients with anaplastic lymphoma kinase (alk)-positive locally advanced or metastatic non-small cell lung cancer (nsclc) who have not previously received an alk-inhibitor
Dosage: CAPSULE
More Information on Dosage
ENSACOVE family patents
7. Fetroja patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9238657 | SHIONOGI INC | Cephalosporin having catechol group |
Nov, 2033
(8 years from now) | |
| US10004750 | SHIONOGI INC | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof |
Sep, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949982 | SHIONOGI INC | Preparation containing cephalosporin having a catechol moiety |
Sep, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-844) | Sep 25, 2023 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 14, 2029 |
Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient
NCE-1 date: 14 November, 2028
Market Authorisation Date: 14 November, 2019
Treatment: Method of treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) comprising administering cefiderocol sulfate tosylate
Dosage: POWDER
More Information on Dosage
FETROJA family patents
8. Flyrcado patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9161997 | GE HLTHCARE | Contrast agents for myocardial perfusion imaging |
Feb, 2026
(9 months from now) | |
| US7344702 | GE HLTHCARE | Contrast agents for myocardial perfusion imaging |
May, 2026
(1 year, 23 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8226929 | GE HLTHCARE | Contrast agents for myocardial perfusion imaging |
Jun, 2028
(3 years from now) | |
| US9603951 | GE HLTHCARE | Methods and apparatus for synthesizing imaging agents, and intermediates thereof |
May, 2031
(6 years from now) | |
| US8936777 | GE HLTHCARE | Methods and apparatus for synthesizing imaging agents, and intermediates thereof |
Jun, 2031
(6 years from now) | |
| US9687571 | GE HLTHCARE | Stabilization of radiopharmaceutical compositions using ascorbic acid |
Nov, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 27, 2029 |
Drugs and Companies using FLURPIRIDAZ F-18 ingredient
NCE-1 date: 27 September, 2028
Market Authorisation Date: 27 September, 2024
Treatment: Method of positron emission tomography (pet) for cardiac imaging
Dosage: SOLUTION
More Information on Dosage
FLYRCADO family patents
9. Iqirvo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943661 | IPSEN | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
Sep, 2024
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7632870 | IPSEN | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
Sep, 2024
(7 months ago) | |
| US11185519 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US12233038 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US11857523 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US11331292 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| US11850223 | IPSEN | Methods of treatment of cholestatic diseases |
Mar, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 10, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Jun 10, 2031 |
Drugs and Companies using ELAFIBRANOR ingredient
NCE-1 date: 10 June, 2028
Market Authorisation Date: 10 June, 2024
Treatment: Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults who have had an inadequate response to udca, or as monotherapy in patients unable to tolerate u...
Dosage: TABLET
More Information on Dosage
IQIRVO family patents
10. Itovebi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8242104 | GENENTECH INC | Benzoxazepin P13K inhibitor compounds and methods of use |
Sep, 2030
(5 years from now) | |
| US9650393 | GENENTECH INC | Benzoxazepin oxazolidinone compounds and methods of use |
Jul, 2036
(11 years from now) | |
| US10851091 | GENENTECH INC | Benzoxazepin oxazolidinone compounds and methods of use |
Jul, 2036
(11 years from now) | |
| US11028100 | GENENTECH INC | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production |
Apr, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8343955 | GENENTECH INC | Benzoxazepin PI3K inhibitor compounds and methods of use |
Sep, 2030
(5 years from now) | |
| US11760753 | GENENTECH INC | Benzoxazepin oxazolidinone compounds and methods of use |
Jul, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2029 |
Drugs and Companies using INAVOLISIB ingredient
NCE-1 date: 10 October, 2028
Market Authorisation Date: 10 October, 2024
Treatment: Combination with palbociclib and fulvestrant for treatment of adults with endocrine-resistant pik3ca-mutated hr-positive her2-negative locally advanced or metastatic breast cancer following recurrence...
Dosage: TABLET
More Information on Dosage
ITOVEBI family patents
11. Jakafi patent expiration
JAKAFI's oppositions filed in EPO
JAKAFI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9662335 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(1 year, 7 months from now) | |
| US7598257 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Dec, 2027
(2 years from now) | |
| US8415362 | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2027
(2 years from now) | |
| US8722693 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9814722 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(1 year, 7 months from now) | |
| US9079912 | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Dec, 2026
(1 year, 7 months from now) | |
|
US9814722 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Jun, 2027
(2 years from now) | |
|
US9079912 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Jun, 2027
(2 years from now) | |
| US8829013 | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
| US10016429 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
| US8822481 | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(3 years from now) | |
|
US8415362 (Pediatric) | INCYTE CORP | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Jun, 2028
(3 years from now) | |
|
US7598257 (Pediatric) | INCYTE CORP | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Jun, 2028
(3 years from now) | |
|
US10016429 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(3 years from now) | |
|
US8822481 (Pediatric) | INCYTE CORP | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(3 years from now) | |
|
US8722693 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(3 years from now) | |
|
US8829013 (Pediatric) | INCYTE CORP | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Dec, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2016 |
| New Indication(I-699) | Dec 04, 2017 |
| Orphan Drug Exclusivity(ODE) | Nov 16, 2018 |
| Orphan Drug Exclusivity(ODE-19) | Nov 16, 2018 |
| Orphan Drug Exclusivity(ODE-79) | Dec 04, 2021 |
| New Indication(I-799) | May 24, 2022 |
| New Indication(I-872) | Sep 22, 2024 |
| M(M-285) | Dec 19, 2025 |
| Orphan Drug Exclusivity(ODE-238) | May 24, 2026 |
| Orphan Drug Exclusivity(ODE-373) | Sep 22, 2028 |
| Pediatric Exclusivity(PED) | Mar 22, 2029 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 16 November, 2011
Treatment: For treatment of steroid-refractory acute graft-versus-host disease (agvhd); For treatment of polycythemia vera (pv) in patients who have had an inadequate response to or are intolerant of hydroxyurea...
Dosage: TABLET
How can I launch a generic of JAKAFI before it's drug patent expiration?
More Information on Dosage
JAKAFI family patents
12. Lazcluze patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9593098 | JANSSEN BIOTECH | Compounds and compositions for modulating EGFR mutant kinase activities |
Oct, 2035
(10 years from now) | |
| US11453656 | JANSSEN BIOTECH | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same |
Apr, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11981659 | JANSSEN BIOTECH | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same |
Apr, 2038
(12 years from now) | |
| US11879013 | JANSSEN BIOTECH | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
May, 2040
(15 years from now) | |
| US12138351 | JANSSEN BIOTECH | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
Apr, 2041
(15 years from now) | |
| US11850248 | JANSSEN BIOTECH | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
Aug, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2029 |
Drugs and Companies using LAZERTINIB MESYLATE ingredient
NCE-1 date: 19 August, 2028
Market Authorisation Date: 19 August, 2024
Treatment: First-line treatment of adults with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 l858r substitution mutations, in combination with amivantam...
Dosage: TABLET
More Information on Dosage
LAZCLUZE family patents
13. Leqselvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561659 | SUN PHARM INDS INC | Treatment of hair loss disorders with deuterated JAK inhibitors |
May, 2037
(12 years from now) | |
| US12076323 | SUN PHARM INDS INC | Treatment of hair loss disorders with deuterated JAK inhibitors |
May, 2037
(12 years from now) | |
| US11919907 | SUN PHARM INDS INC | Deuterated JAK inhibitor and uses thereof |
May, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 25, 2029 |
Drugs and Companies using DEURUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 25 July, 2028
Market Authorisation Date: 25 July, 2024
Treatment: Treatment of adult patients with alopecia areata
Dosage: TABLET
More Information on Dosage
LEQSELVI family patents
14. Livdelzi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7301050 | GILEAD SCIENCES INC | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
Aug, 2025
(2 months from now) | |
| US7709682 | GILEAD SCIENCES INC | Lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives |
Sep, 2026
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11596614 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| US10272058 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| US11406611 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| US9486428 | GILEAD SCIENCES INC | Treatment of intrahepatic cholestatic diseases |
Mar, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 14, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Aug 14, 2031 |
Drugs and Companies using SELADELPAR LYSINE ingredient
NCE-1 date: 14 August, 2028
Market Authorisation Date: 14 August, 2024
Treatment: Treatment of primary biliary cholangitis (pbc)
Dosage: CAPSULE
More Information on Dosage
LIVDELZI family patents
15. Lumisight patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11592396 | LUMICELL | Methods and systems for spatially identifying abnormal cells |
Sep, 2030
(5 years from now) | |
| US9763577 | LUMICELL | Imaging agent for detection of diseased cells |
Sep, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9155471 | LUMICELL | Methods and systems for spatially identifying abnormal cells |
Oct, 2031
(6 years from now) | |
| US10285759 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(6 years from now) | |
| US9032965 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(6 years from now) | |
| US9532835 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2029 |
Drugs and Companies using PEGULICIANINE ACETATE ingredient
NCE-1 date: 17 April, 2028
Market Authorisation Date: 17 April, 2024
Treatment: A method comprising administering pegulicianine to a human and obtaining an image of a tumor bed after tumor resection to distinguish in situ cancer cells from healthy cells
Dosage: POWDER
More Information on Dosage
LUMISIGHT family patents
16. Miplyffa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9884058 | ZEVRA DENMARK | Use of Hsp70 as a regulator of enzymatic activity |
Jun, 2029
(4 years from now) | |
| US9289472 | ZEVRA DENMARK | Use of HSP70 as a regulator of enzymatic activity |
Aug, 2029
(4 years from now) | |
| US11045460 | ZEVRA DENMARK | Use of Hsp70 as a regulator of enzymatic activity |
Aug, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 20, 2029 |
| Orphan Drug Exclusivity(ODE-496) | Sep 20, 2031 |
Drugs and Companies using ARIMOCLOMOL CITRATE ingredient
NCE-1 date: 20 September, 2028
Market Authorisation Date: 20 September, 2024
Treatment: Use of arimoclomol, in combination with miglustat, for treatment of neurological manifestations of niemann-pick disease type c (npc)
Dosage: CAPSULE
More Information on Dosage
MIPLYFFA family patents
17. Ohtuvayre patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9062047 | VERONA PHARMA | Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound |
Aug, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10945950 | VERONA PHARMA | Liquid inhalation formulation comprising RPL554 |
Sep, 2035
(10 years from now) | |
| US9956171 | VERONA PHARMA | Liquid inhalation formulation comprising RPL554 |
Sep, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 26, 2029 |
Drugs and Companies using ENSIFENTRINE ingredient
NCE-1 date: 26 June, 2028
Market Authorisation Date: 26 June, 2024
Treatment: For the maintenance treatment of chronic obstructive pulmonary disease (copd) in adult patients
Dosage: SUSPENSION
More Information on Dosage
OHTUVAYRE family patents
18. Ojemda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8293752 | DAY ONE BIOPHARMS | Compounds useful as Raf kinase inhibitors |
Aug, 2031
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10426782 | DAY ONE BIOPHARMS | Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparation |
Jun, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 23, 2029 |
| Orphan Drug Exclusivity(ODE-478) | Apr 23, 2031 |
Drugs and Companies using TOVORAFENIB ingredient
NCE-1 date: 23 April, 2028
Market Authorisation Date: 23 April, 2024
Treatment: NA
Dosage: FOR SUSPENSION; TABLET
More Information on Dosage
OJEMDA family patents
19. Recarbrio patent expiration
Can you believe RECARBRIO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8487093 | MSD MERCK CO | β-lactamase inhibitors |
Mar, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 16, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Jul 16, 2029 |
Drugs and Companies using CILASTATIN SODIUM; IMIPENEM; RELEBACTAM ingredient
NCE-1 date: 16 July, 2028
Market Authorisation Date: 16 July, 2019
Treatment: Treatment of complicated urinary tract infections, including pyelonephritis (cuti)
Dosage: POWDER
More Information on Dosage
RECARBRIO family patents
20. Revuforj patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10683302 | SYNDAX | Inhibitors of the menin-MLL interaction |
Jun, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11479557 | SYNDAX | Inhibitors of the menin-MLL interaction |
Jun, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2029 |
| Orphan Drug Exclusivity(ODE-502) | Nov 15, 2031 |
| Orphan Drug Exclusivity(ODE-504) | Nov 15, 2031 |
| Orphan Drug Exclusivity(ODE-505) | Nov 15, 2031 |
Drugs and Companies using REVUMENIB CITRATE ingredient
NCE-1 date: 15 November, 2028
Market Authorisation Date: 15 November, 2024
Treatment: Treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2a gene (kmt2a) translocation in adult and pediatric patients 1 year and older
Dosage: TABLET
More Information on Dosage
REVUFORJ family patents
21. Rezdiffra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7452882 | MADRIGAL | Thyroid hormone analogs |
Sep, 2026
(1 year, 4 months from now) | |
| US11564926 | MADRIGAL | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(8 years from now) | |
| US9266861 | MADRIGAL | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11986481 | MADRIGAL | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(8 years from now) | |
| US10376517 | MADRIGAL | Methods of synthesizing thyroid hormone analogs and polymorphs thereof |
Sep, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 14, 2029 |
Drugs and Companies using RESMETIROM ingredient
NCE-1 date: 14 March, 2028
Market Authorisation Date: 14 March, 2024
Treatment: Treatment of adults with noncirrhotic nonalcoholic steatohepatitis (nash) with moderate to advanced liver fibrosis (consistent with stages f2 to f3 fibrosis)
Dosage: TABLET
More Information on Dosage
REZDIFFRA family patents
22. Sofdra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8147809 | BOTANIX SB | Soft anticholinergic esters |
Mar, 2027
(1 year, 10 months from now) | |
| US11584715 | BOTANIX SB | Crystalline form of sofpironium bromide and preparation method thereof |
May, 2040
(15 years from now) | |
| US11566000 | BOTANIX SB | Crystalline form of sofpironium bromide and preparation method thereof |
May, 2040
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8628759 | BOTANIX SB | Soft anticholinergic esters |
Nov, 2026
(1 year, 6 months from now) | |
| US9895350 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(8 years from now) | |
| US9220707 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(8 years from now) | |
| US9492429 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(8 years from now) | |
| US10383846 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(8 years from now) | |
| US10961191 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(9 years from now) | |
| US10952990 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(9 years from now) | |
| US11026919 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(9 years from now) | |
| US10959983 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(9 years from now) | |
| US11034652 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(9 years from now) | |
| US11084788 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(9 years from now) | |
| US11052067 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(9 years from now) | |
| US10947192 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(9 years from now) | |
| US11123325 | BOTANIX SB | Formulation for soft anticholinergic analogs |
Jul, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2029 |
Drugs and Companies using SOFPIRONIUM BROMIDE ingredient
NCE-1 date: 20 June, 2028
Market Authorisation Date: 18 June, 2024
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: GEL, METERED
More Information on Dosage
SOFDRA family patents
23. Tasigna patent expiration
TASIGNA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169791 | NOVARTIS | Inhibitors of tyrosine kinases |
Jul, 2023
(1 year, 9 months ago) | |
| US8415363 | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(1 year, 2 months from now) | |
| US8163904 | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Aug, 2028
(3 years from now) | |
| US9061029 | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Apr, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7169791 | NOVARTIS | Inhibitors of tyrosine kinases |
Jul, 2023
(1 year, 9 months ago) | |
|
US7169791 (Pediatric) | NOVARTIS | Inhibitors of tyrosine kinases |
Jan, 2024
(1 year, 3 months ago) | |
| US8501760 | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jul, 2026
(1 year, 2 months from now) | |
| US8389537 | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jul, 2026
(1 year, 2 months from now) | |
|
US8389537 (Pediatric) | NOVARTIS | Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(1 year, 8 months from now) | |
|
US8415363 (Pediatric) | NOVARTIS | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
Jan, 2027
(1 year, 8 months from now) | |
|
US8501760 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib or its salt |
Jan, 2027
(1 year, 8 months from now) | |
| US8293756 | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Sep, 2027
(2 years from now) | |
|
US8293756 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising nilotinib hydrochloride monohydrate |
Mar, 2028
(2 years from now) | |
|
US8163904 (Pediatric) | NOVARTIS | Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide |
Feb, 2029
(3 years from now) | |
|
US9061029 (Pediatric) | NOVARTIS | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity |
Oct, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2012 |
| New Indication(I-627) | Jun 17, 2014 |
| Orphan Drug Exclusivity(ODE) | Oct 29, 2014 |
| New Dosing Schedule(D-170) | Dec 22, 2020 |
| New Patient Population(NPP) | Mar 22, 2021 |
| Orphan Drug Exclusivity(ODE-171) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-172) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-380) | Sep 23, 2028 |
| Pediatric Exclusivity(PED) | Mar 23, 2029 |
Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 23 March, 2028
Market Authorisation Date: 22 March, 2018
Treatment: A method for the treatment of leukemias; Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml); Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml...
Dosage: CAPSULE
How can I launch a generic of TASIGNA before it's drug patent expiration?
More Information on Dosage
TASIGNA family patents
24. Tryvio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8324232 | IDORSIA | 4-pyrimidinesulfamide derivative |
Sep, 2029
(4 years from now) | |
| US10919881 | IDORSIA | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
Feb, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11174247 | IDORSIA | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
Nov, 2037
(12 years from now) | |
| US11787782 | IDORSIA | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases |
Mar, 2038
(12 years from now) | |
| US11680058 | IDORSIA | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
Jul, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2029 |
Drugs and Companies using APROCITENTAN ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 19 March, 2024
Treatment: Treatment of hypertension in combination with other antihypertensive drugs, including an angiotensin receptor blocker, to lower blood pressure in adult patients who are not adequately controlled on ot...
Dosage: TABLET
More Information on Dosage
TRYVIO family patents
25. Vafseo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8598210 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Jun, 2027
(2 years from now) | |
| USRE47437 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Jun, 2027
(2 years from now) | |
| US8343952 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Aug, 2027
(2 years from now) | |
| US7811595 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Mar, 2028
(2 years from now) | |
| US11065237 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(9 years from now) | |
| US10149842 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(9 years from now) | |
| US9701636 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8940773 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Jun, 2027
(2 years from now) | |
| US8323671 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Apr, 2028
(2 years from now) | |
| US11857543 | AKEBIA | Compositions and methods for treating anemia |
Jun, 2034
(9 years from now) | |
| US9987262 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(9 years from now) | |
| US11324734 | AKEBIA | Compositions and methods for treating anemia |
Mar, 2036
(10 years from now) | |
| US11844756 | AKEBIA | Compositions and methods for treating anemia |
Mar, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2029 |
Drugs and Companies using VADADUSTAT ingredient
NCE-1 date: 27 March, 2028
Market Authorisation Date: 27 March, 2024
Treatment: Treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months
Dosage: TABLET
More Information on Dosage
VAFSEO family patents
26. Voranigo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9579324 | SERVIER | Therapeutically active compounds and their methods of use |
Jul, 2034
(9 years from now) | |
| US10172864 | SERVIER | Therapeutically active compounds and their methods of use |
Jul, 2034
(9 years from now) | |
| US11345677 | SERVIER | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same |
Jan, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11844758 | SERVIER | Therapeutically active compounds and their methods of use |
Dec, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2029 |
| Orphan Drug Exclusivity(ODE-491) | Aug 06, 2031 |
Drugs and Companies using VORASIDENIB ingredient
NCE-1 date: 06 August, 2028
Market Authorisation Date: 06 August, 2024
Treatment: A method of treating a glioma characterized by an idhi mutation following surgery, wherein the glioma is grade 2 astrocytoma or oligodendroglioma; A method of treating a cancer characterized by an idh...
Dosage: TABLET
More Information on Dosage
VORANIGO family patents
27. Voydeya patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9796741 | ALEXION PHARMS INC | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders |
Feb, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12076319 | ALEXION PHARMS INC | Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria |
Aug, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2029 |
| Orphan Drug Exclusivity(ODE-476) | Mar 29, 2031 |
Drugs and Companies using DANICOPAN ingredient
NCE-1 date: 29 March, 2028
Market Authorisation Date: 29 March, 2024
Treatment: Treatment of extravascular hemolysis (evh) in adults with paroxysmal nocturnal hemoglobinuria (pnh) as add-on therapy to ravulizumab or eculizumab
Dosage: TABLET
More Information on Dosage
VOYDEYA family patents
28. Xenleta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6753445 | HONG KONG | Pleuromutilin derivatives having antibacterial activity |
Jul, 2021
(3 years ago) | |
| US8153689 | HONG KONG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Mar, 2028
(2 years from now) | |
| US8071643 | HONG KONG | Pleuromutilin derivatives for the treatment of diseases mediated by microbes |
Jan, 2029
(3 years from now) | |
| US9120727 | HONG KONG | Process for the preparation of pleuromutilins |
May, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 19, 2029 |
Drugs and Companies using LEFAMULIN ACETATE ingredient
NCE-1 date: 19 August, 2028
Market Authorisation Date: 19 August, 2019
Treatment: Treatment of adults with community-acquired bacterial pneumonia caused by susceptible microorganisms
Dosage: TABLET; SOLUTION
More Information on Dosage
XENLETA family patents
29. Xolremdi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10953003 | X4 PHARMS | Methods for treating cancer |
Dec, 2036
(11 years from now) | |
| US10610527 | X4 PHARMS | Methods for treating immunodeficiency disease |
Dec, 2036
(11 years from now) | |
| US11219621 | X4 PHARMS | Methods for treating immunodeficiency disease |
Dec, 2036
(11 years from now) | |
| US10548889 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(13 years from now) | |
| US12115156 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(13 years from now) | |
| US11045461 | X4 PHARMS | Compositions of CXCR4 inhibitors and methods of preparation and use |
Dec, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 26, 2029 |
| Orphan Drug Exclusivity(ODE-480) | Apr 26, 2031 |
Drugs and Companies using MAVORIXAFOR ingredient
NCE-1 date: 26 April, 2028
Market Authorisation Date: 26 April, 2024
Treatment: Treatment of patients 12 years and older with warts, hypogammaglobulinemia, infections, and myelokathexis (whim) syndrome
Dosage: CAPSULE
More Information on Dosage
XOLREMDI family patents
30. Yorvipath patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8906847 | ASCENDIS PHARMA BONE | Prodrug comprising a drug linker conjugate |
Apr, 2031
(5 years from now) | |
| US11918628 | ASCENDIS PHARMA BONE | Controlled-release PTH compound |
Sep, 2037
(12 years from now) | |
| US11890326 | ASCENDIS PHARMA BONE | Controlled-release PTH compound |
Sep, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11857603 | ASCENDIS PHARMA BONE | PTH compounds with low peak-to-trough ratios |
Sep, 2037
(12 years from now) | |
| US11759504 | ASCENDIS PHARMA BONE | PTH compounds with low peak-to-trough ratios |
Sep, 2037
(12 years from now) | |
| US11590207 | ASCENDIS PHARMA BONE | Dosage regimen for a controlled-release PTH compound |
Sep, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 09, 2027 |
| New Chemical Entity Exclusivity(NCE) | Aug 09, 2029 |
| Orphan Drug Exclusivity(ODE-492) | Aug 09, 2031 |
Drugs and Companies using PALOPEGTERIPARATIDE ingredient
NCE-1 date: 09 August, 2028
Market Authorisation Date: 09 August, 2024
Treatment: Treatment of hypoparathyroidism in adults
Dosage: SOLUTION
More Information on Dosage
YORVIPATH family patents
31. Zelsuvmi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8956658 | LNHC | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
May, 2026
(1 year, 27 days from now) | |
| US8282967 | LNHC | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
May, 2026
(1 year, 27 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9737561 | LNHC | Topical gels and methods of using the same |
Aug, 2030
(5 years from now) | |
| US10376538 | LNHC | Topical gels and methods of using the same |
Aug, 2030
(5 years from now) | |
| US9526738 | LNHC | Topical gels and methods of using the same |
Sep, 2031
(6 years from now) | |
| US9289442 | LNHC | Topical compositions |
Jul, 2032
(7 years from now) | |
| US10265334 | LNHC | Anhydrous compositions |
Jul, 2032
(7 years from now) | |
| US9855211 | LNHC | Topical compositions and methods of using the same |
Feb, 2034
(8 years from now) | |
| US11285098 | LNHC | Topical compositions and methods of using the same |
Feb, 2034
(8 years from now) | |
| US10258564 | LNHC | Topical compositions and methods of using the same |
Nov, 2034
(9 years from now) | |
| US11040006 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(10 years from now) | |
| US11723858 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(10 years from now) | |
| US10736839 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(10 years from now) | |
| US10322081 | LNHC | Topical antiviral compositions and methods of using the same |
Jul, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 05, 2029 |
Drugs and Companies using BERDAZIMER SODIUM ingredient
NCE-1 date: 06 January, 2028
Market Authorisation Date: 05 January, 2024
Treatment: Method of treating skin ailment with nitric oxide releasing macromolecules and hydrophilic gel; Method of application of topical pharmaceutical composition to treat dermatological condition; Method of...
Dosage: GEL
More Information on Dosage
ZELSUVMI family patents